Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

I'm a little surprised that ARNA has had so much of a pullback after it rallied from the DEA decision. I was really expecting it to at least have a few good days before a correction. I'm still long this position and i'm sure the sales will do fine once it hits the market.

It seems like Americans are always looking for that pill that takes care of their needs especially when it comes to dieting. The market here is beyond vast and the drug has been approved! If this diet aid is marketed well I believe we are looking at huge amounts of sales. Go Belviq!!

ARNA stands poised on the edge of a major blockbuster diet drug that has the potential to hit the coveted billion dollar annual status.

Weight loss drug will have great acceptance in the market

1. US Launch of Anti-Obesity Drug
2. EU Approval
4. Lucrative Partnership Royalties
5. New Partnerships

I'm new to the investing world, but this company is soon to release the first FDA approved weight loss drug in over a decade. Also, the DEA has said that it's non addictive and given the green light. 68% of Americans are overweight or obese, so I can't see how a company producing a drug that will be used by roughly 200 million people will go wrong.

Stock price will be based solely on sales expectations and revenue RESULTS. Everything else is just noise.

I find that Arena has done a great job in setting up Belviq to achieve it's market potential, which addresses a global problem and is huge, but Arena will do well because it continues to Partner and develop a larger pipeline. In addition, once Belviq has past many approval hurdles, there are many other opportunities for Belviq to address other large health issues. I believe that once Arena's Partners begin marketing, there will be no doubt that Arena will outperform for many years to come, provided that they are not bought out

Euro approval and strong US sales this this sweet stick higher on 2013. Look for 15 by summer with maybe $20 by end of 2013

Based on my unreliable psychic powers of guessing about medical field.

Yes

New obesity drug with a novel mechanism of action will likely be much safer than stimulant alternatives which carry a high potential for cardiovascular events and abuse. This drug, which is not a controlled substance, stands to make this company a lot of money considering the obesity/diabetes epidemic in this country. Given this, I also anticipate eventual coverage by most major third party payers which will in turn increase the number of prescriptions for Belviq (lorcaserin)

Short the launch.

OUTPERFOM MARKET --RISK THAT WILL NOT BE APPROVED IN EUROPE AND LESS EFFECTIVE THAN VVUS PRODUCT ARE OVERBLOWN.

this is a possible game changer...obesity and diabetes are in real large supply worldwide and Belviq treats both... without side effects

Huge potential market.

The weight loss market is huge. Consumers will flock to both drugs after it hits the market. Both will exceed all expectations, and ARNA is undervalued

Big breakout, on LONG term charts.

belviq is going to be the billion dollar obesity fighting drug that will be the rage in the coming years.